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Obstructive lung disease is the major cause of morbidity and mortality in cystic fibrosis (CF). To
identify risk factors contributing to FEV1 decline in CF patients, we carried out a retrospective
analysis of clinical and pulmonary function data in a population of CF patients followed up for 5
years and studied the correlation between clinical data and FEV1 decline.
Fifty-one adult CF patients were studied. The FEV1 decline was related to the following clin-
ical characteristics: CFTR genotype, age, gender, weight, height, age at diagnosis, baseline
FEV1, pancreatic function, presence of airway infection, pancreatic insufficiency and diabetes,
number of exacerbations/year and intravenous (i.v.) antibiotic courses/year.
Both the number of exacerbations/year and the number of i.v. antibiotic courses/year were
strongly related to the FEV1 decline. Patients with airway infection or with diabetes had signif-
icantly lower FEV1 values during the study as compared with non-infected patients or patients
without diabetes; however, both the presence of airway infection or diabetes did not affect
the FEV1 decline.
These results suggest that the aggressive treatment of disease exacerbations is crucial for
delaying lung function decline in CF.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Cystic fibrosis (CF) is the most common lethal autosomal
recessive disorder in the white population. Obstructive lung39 11 9038674.
ito.it (V. De Rose).
8 Elsevier Ltd. All rights reserveddisease is the major cause of morbidity and mortality in
CF.1,2 Although the overall survival has improved markedly
over the past two decades, the natural history of the
disease continues to be characterized by a steady decline in
lung function. Whereas there is an association between
CFTR genotype and pancreatic function, there is a wide
variation in the severity of lung disease, even in patients
with the same CFTR genotype.3,4 This suggests that other.
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treatment strategies are important determinants of lung
disease severity. Since progressive lung disease is the main
determinant of morbidity and mortality in CF, it is essential
to identify factors that can explain and predict its vari-
ability; the identification of such factors may allow earlier
intervention with more aggressive therapy. While previous
studies of CF patients have shown that the yearly decline of
Forced Expiratory Volume in 1 s (FEV1) is the most impor-
tant variable predicting mortality,5,6 the factors affecting
long-term decline in lung function are still only in part
known.
To identify risk factors contributing to lung function
decline, we carried out a retrospective analysis of clinical
and pulmonary function data in a population of adult
patients with CF followed up for 5 years and studied the
correlation between clinical data and the rate of FEV1
deterioration, usingmainly mixedmodel regression analysis.Patients and methods
A cohort of 51 adult CF patients, representing the patient
population systematically followed at the CF Center of the
Respiratory Disease Division, University of Turin, during the
period 2001e2005 was studied.
Patients with allergic bronchopulmonary aspergillosis
(defined according to Nelson’s criteria7 and 2001 Cystic
Fibrosis Foundation Consensus Conference criteria8),
pneumothorax, or patients who underwent lung trans-
plantation were excluded from the study.
The rates of FEV1 decline during the observation period
were analyzed and related to clinical data.
All data were extracted from medical records, at the
time of stable clinical conditions, for each year of the study
period (2001e2005). Patients were considered clinically
stable when there was no evidence of exacerbations during
the previous 2 months. Data recorded included age, sex,
weight, height, age at diagnosis of CF, CFTR mutations,
FEV1, body mass index (BMI), the presence of pancreatic
insufficiency (PI), CF-related diabetes mellitus (CFRD),
chronic infection with Pseudomonas aeruginosa, or Bur-
kholderia cepacia, or other non-fermentative Gram-nega-
tive rods, the number of exacerbations per year, and the
number of intravenous (i.v.) antibiotic courses per year.
The diagnosis of CF was based on a typical clinical profile
with positive sweat test and/or identification of CFTR
mutations.
Patients were classified as pancreatic insufficient on the
basis of the following criteria: low fecal elastase concen-
tration (<200 mg elastase 1), and/or an abnormal 3-day
fecal fat balance study in conjunction with a clinical history
of steatorrhea.9 CFRD was defined according to 1999
Consensus Conference criteria.10 BMI was calculated from
the ratio of weight/height2 (kg/m2).
Chronic infection was defined, according to the 2000
European Consensus criteria,11 as persistent presence of
bacteria in sputum for at least 6 months, based on at least
three positive cultures with at least one-month intervals
between them.
A pulmonary exacerbation was defined as the presence of
at least three of the following signs and symptoms: anincrease in sputum purulence and volume, increased respi-
ratory rate or dyspnea, increased cough, weight loss and
anorexia, temperature above 38 C on more than one
occasion in the previous week, new findings on chest radio-
graph, or a decrease in FEV1 of 10% ormore from a previously
recorded value when the patient was clinically stable.12
Antibiotic treatment of pulmonary exacerbations was
done according to published guidelines11,13: treatment of
moderate-severe exacerbations requiring hospitalization
consisted in an association of at least two antibiotics,
chosen according to the in vitro sensitivity of the bacteria
isolated from sputum (usually an antipseudomonal beta-
lactam and an aminoglycoside) and administered i.v., at
high doses, for 14e21 days or until pulmonary function
recover to baseline values; mild exacerbations were
treated by oral antibiotics chosen according to the in vitro
sensitivity of the bacteria isolated from sputum.
Pulmonary function was assessed by FEV1, using a Vmax
spirometer (Sensormedics, Milan, Italy). The best of three
technically acceptable maneuvers was selected according
to the American Thoracic Society guidelines.14 The total
number of spirometric tests used in the analysis was 256: 48
subjects had at least 5 observations, 3 subjects only 4
observations. Some patients had more than one measure-
ment each year (range: 90% of patients had 1 measurement
each year, 7% of patients had 2 measurements each year,
and 3% had 3 measurements each year): to minimize vari-
ability due to insufficient patient effort or inherent test
variability, we used the best yearly value for each patient,
considering as test date the proper measurement day.
Mutation analysis of the CFTR gene was done as previ-
ously described.15 Genotype was defined as 0, 1 or 2 on the
basis of unknown, severe or mild mutations carried by each
individual.
The study conformed to the declaration of Helsinky and
written informed consent was obtained from all subjects,
before accessing their patient information.Statistical analysis
The sample size was 51 subjects with a mean of 5 obser-
vations for each subject, for a total of 256 observations in
a repeated measure design.
The sample size in a non-experimental or retrospective
study is predetermined, as well as the number of observa-
tions for subject. A posteriori we could estimate as signif-
icant at 5% (alfa error), with a power of 0.80, a mean yearly
within subjects FEV1 change 20 ml and a 40 ml of mean
FEV1 difference between subjects in a repeated measure
design. A minor size of the effect could be considered not
clinically relevant.
Longitudinal FEV1 data were analyzed using a linear
mixed model (Stata 9.0 Stata Co: procedure xtmixed16),
containing both fixed effects and random effects, assuming
that the FEV1 (adjusted for sex, age in years at the first visit
centred to the general mean, height and weight at each
control) follows a linear regression versus time for each
patient with random patient-specific slope and intercept;
potential predictors were considered as fixed effects. The
time was expressed in years from the first measurement
(days/365.25).
Table 1 Clinical characteristics of the study cohort at the
enrollment in the study.
Patients (N ) 51
Sex (M/F) 28/23
Age, years (M  SD) 29.1  10.7
Age at diagnosis
<18 yrs, N (%) 36 (70.6)
18 years, N (%) 15 (29.4)
Pancreatic insufficiency, N (%) 28/51 (55)
Diabetes mellitus, N (%) 8/51 (15.7)
BMI, kg/m2 (M  SD) 21.88  3.3
FEV1, L (M  SD) 2.425  0. 957
FEV1 (% predicted) (M  SD) 69.9  21.7
FEV1 e predicted, L (M  SD) 0.900  0.823
No chronic airway infection, N (%) 12/51 (21)
Chronic infection by
 P. aeruginosa, N (%) 24/51 (47)
 B. cepacia, N (%) 8/51 (16)
 Other non-fermentative
Gram-negative rods, N (%)
7/51 (14)
CFTR genotype (mutation class)
 Severe, N (%) 18/51 (35)
 Mild, N (%) 8/51 (16)
 Unknown, N (%) 25/51 (49)
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within observations if representing a condition that we could
expect not varying and not measured each time, and time-
varying if measured in more than an occasion and expected
to change over time.
Time constant variables were height in cm (centred to
the general mean), sex (males Z 1, females Z 0), age at
the first observation, age at the diagnosis, genotype
(unknown: 0; severe: 1, mild: 2), PI (0 Z NO, 1 Z YES).
Time-varying covariates were chronic infection with
P. aeruginosa, or with other non-fermentative Gram-
negative rods, or with B. cepacia, CFRD, BMI, number of
exacerbations per year, number of courses of i.v. antibiotics
per year.
Main effects and interactions not significant at 5% level
were removed from the final model: interactions between
time and time-varying covariates, if significant at 5% level,
were retained without main effects (nested model)17 if the
last were not significant at 5% level.
With the aim to control for different unobserved condi-
tions before the first visit in each model the mean 5 years
FEV1 (centred to the general mean) was forced in the
models; the time fixed effect was also forced.
The error distribution of the linear mixed models was
assumed to be Gaussian.
The patient-specific slopes and intercepts averaged
among predictors category, considering both fixed and
random part of the estimation (empirical Bayes estimates),
were plotted.16
Results
Clinical characteristics of patients
Fifty-one adult CF patients (28 males and 23 females, mean
age: 29.1  10.7 years, range: 17e63 years) were included
in the study. The clinical characteristics of the patients
studied, at the inclusion in the study (year 2001), are
reported in Table 1. The mean age at entry was 29.1  10.7
years; mean age at diagnosis was 16  15.3 years: in
particular, in 15 patients the diagnosis of CF was made at
age 18 years. PI was present in 28 patients (55%),
whereas only 8 patients (15.7%) were also affected by
CFRD; mean BMI values were 21.8  3.3 kg/m2. Mean FEV1
values were 2.425  0.957 L (FEV1% predicted:
69.9  21.7%), with a mean predicted deviation of
0.900  0.823 L, at the first year of observation. Most of
the patients studied had chronic airway infection: in 24
cases (47%) with P. aeruginosa, in 7 cases (14%) with other
non-fermentative Gram-negative rods, and in 8 cases (16%)
with B. cepacia.
Pulmonary function and clinical parameters
FEV1 measurements were obtained in the 51 patients
studied for 5 years, with a mean of 5 observations for each
subject, for a total of 256 observations. A yearly mean
FEV1 reduction of 76  49.5 ml was observed in these
patients.
The relationship between the FEV1 decline during the
five years of observation and the clinical parametersstudied is shown in Table 2 and represented graphically in
Figs. 2 and 3.
Patients with airway infection with non-fermentative
Gram-negative rods or B. cepacia showed significantly
lower FEV1 values during the study as compared with non-
infected patients (p < 0.001 for both comparisons);
however, there were no significant differences in FEV1
decline between the groups. Similarly, the presence of
CFRD did not seem to affect the rate of FEV1 decline during
the study period, although patients with CFRD showed
significantly lower FEV1 values as compared with patients
without CFRD (p < 0.04). In contrast, there was a strong
relationship between the number of exacerbations/year
and the FEV1 decline during the five years of observation
(p < 0.006), with a FEV1 loss of about 30 ml for each
exacerbation episode. The distribution of the study pop-
ulation according to the number of exacerbations/year
during the period of observation is reported in Fig. 1. As
shown in Fig. 2, patients who experienced three or more
exacerbations/year showed, at the end of the fifth year of
observation, a total decrease in FEV1 of 183.56 ml and of
157.35 ml greater than patients who did not experienced
any exacerbation or had had only one/two exacerbation/
year, respectively. A similar effect on FEV1 decline was
observed with regard to the number of i.v. courses of
antibiotic therapy/year: patients treated with i.v. antibi-
otic therapy showed an FEV1 loss of 31 ml per each yearly
course of therapy as compared with patients who did not
undergo i.v. antibiotic therapy (p < 0.03, Table 2 and
Fig. 3).
No significant effect on FEV1 decline was observed for
any of the other clinical parameters studied: i.e. sex, age
at diagnosis, class of CFTR mutations, BMI levels, presence
or absence of PI or chronic infection with P. aeruginosa.
Table 2 Mixed model regression analysis for the association between the mean decline in FEV1 and the clinical parameters
studied.a
Covariate Coefficient (ml/yr) 95%CI P value
Main effects Time (year) 46.8 60.5 50.9 0.86
Chronic infection with non-fermentative
Gram-negative rods (2001)
730.2 1136.1 324.3 0.001
Chronic infection with B. cepacia (2001) 811.8 1296.6 327.0 0.001
Diabetes mellitus 417.1 818.6 15.7 0.04
Interactions with time Number of exacerbations/year 30.2 51.6 8.8 0.006
Number of courses of intravenous
antibiotics/year
31.0 58.8 3.1 0.03
a Dependent variable: FEV1 e L adjusted for sex, age at the first visit, BMI, height and mean individual FEV1 e general mean of FEV1.
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To identify risk factors contributing to lung function decline
in CF patients, we carried out a retrospective analysis of
clinical and pulmonary function data in a population of
adult CF patients and studied the correlation between
clinical data and the rate of FEV1 deterioration, during five
years of observation.
We showed that there is a strong relationship between
both the number of exacerbations/year and the number of
i.v. courses of antibiotic therapy/year and the FEV1 decline
during the five years of observation. Although significantly
lower values of FEV1 during the study were observed in
patients with chronic airway infection with non-fermenta-
tive Gram-negative rods or B. cepacia as compared with
non-infected patients, and in patients with CFRD as
compared with patients without CFRD, none of them seems
to affect the rate of FEV1 decline during the study period.
Previous studies have shown that risk factors for accel-
erated decline in lung function in CF include female sex,Figure 1 Distribution of the study population according to the nhigher baseline FEV1, poor nutritional status, PI, CFRD and
respiratory tract colonization with P. aeruginosa and
B. cepacia.5,18e26 Recently, Konstan et al.26 showed that
the frequency of pulmonary exacerbations treated with
intravenous antibiotics and observed during a 1-year lead-in
period was associated with FEV1 decline in CF children and
adolescents. Interestingly, Martinez-Garcia et al.27 also
reported that more frequent severe exacerbations were
associated with an accelerated FEV1 decline in adult
patients with non-cystic fibrosis bronchiectasis. To our
knowledge our observation of a tight relationship between
the number of exacerbations/year and the FEV1 decline in
adult CF patients is a novel finding in this population, and it
extends previous observations and further strengthens the
role of disease exacerbations in the impairment of pulmo-
nary function. Our results differ however from those of
Ellaffi et al.28: these authors were unable to find an asso-
ciation between severe exacerbations and lung function
decline during the 12 months after exacerbations in CF
patients, although FEV1 values were significantly lowerumber of exacerbations/year during the period of observation.
Figure 2 FEV1 growth curve (empirical Bayes estimates: fixed and random effects) by year from the first visit and averaged by
number of exacerbations/year during the study period (0, 1e2, 3).
FEV1 decline in cystic fibrosis 411during this period as compared with FEV1 values measured
during the year preceding pulmonary exacerbations. This
discrepancy might be explained by the shorter follow up
period (1 year) in this study as compared to our study (5
years).
Recurrent pulmonary exacerbations are associated with
greater mortality and morbidity in CF patients.29,30 In our
Center, pulmonary exacerbations are treated with aggres-
sive antibiotic therapy until pulmonary function recovers to
baseline values. Thus, our observation that the number of
exacerbations/year affects the rate of FEV1 decline seems
to suggest that, independently from the outcome of the
exacerbation events, a greater number of exacerbations is
capable per se of inducing airway wall damage; this might
be the consequence of a persistent subclinical airway
inflammation leading over time to further impairment of
lung function; accordingly to this hypothesis, Downey et al.Figure 3 FEV1 growth curve (empirical Bayes estimates: fixed an
number of i.v. courses of antibiotic therapy/year during the studyrecently showed that antibiotic treatment of pulmonary
exacerbations in CF patients was able to decrease systemic,
but not local inflammation.31 Although we cannot exclude
that the effect on lung function we observed might be due
to a more severe disease in patients with a greater number
of exacerbations, this is unlikely as multiple regression
analysis corrected for confounding effects of parameters
affecting disease severity.
In our study, we did not included among predictive vari-
ables the extent and severity of bronchiectasis, however
previous studies appear to suggest that this parameter is not
correlated or only weakly correlated to lung function.32e34
Interestingly, in the present study, an effect on FEV1
decline was also observed with regard to the number of i.v.
antibiotic courses per year. This observation further
strengthens the role of exacerbations in disease progression,
suggesting that the severity of the exacerbations playsd random effects) by year from the first visit and averaged by
period (0, 1, 2).
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dose and duration of antibiotic treatment were not included
in our analysis, we can safely exclude that these parameters
could have affected the results; in fact, as we discussed
above, in our Center, pulmonary exacerbations are treated,
according to published guidelines and standardized proto-
cols, with aggressive antibiotic therapy until pulmonary
function recover to baseline values.
Consistent with previous studies25,26,35 we observed that
patients with chronic infections by Gram-negative rods and
B. cepacia had significantly lower FEV1 values during the
study period compared with patients without infections.
However, in contrast with previous studies,23e25 we did not
observe a significant effect of airway infection by these
microorganisms or P. aeruginosa on FEV1 decline. This
discrepancy might be due to the smaller number of
patients without infection in our study or to the shorter
period of follow up; in fact, as our patients were all adult
they were chronically infected since several years, and in
such a group of patients a longer follow up period might be
needed to detect the effect of chronic infection on FEV1
decline; this hypothesis is consistent with the findings of
Konstan and coworkers26: these authors studied the risk
factors for FEV1 decline in 3 different age groups of
children and adolescents with CF and observed that
infection with P. aeruginosa was associated with FEV1
decline in children aged 6e12 years but not in 13e17 years
old adolescents.
The presence of CFRD did not affect the FEV1 decline
during the study period, although patients with CFRD
showed significantly lower FEV1 values than patients
without CFRD. Progressive clinical deterioration in patients
with CFRD was reported in some studies, but not in oth-
ers.22,35e38 Our results are in agreement with those repor-
ted by Koch et al.38 who found that patients with CFRD had
significantly lower FEV1 values compared with patients
without CFRD, but they differ from those of Schaedel
et al.22 who found a more rapid FEV1 decline in diabetic
than in non-diabetic patients. This discrepancy might be
due to the small number of patients with CFRD in our
population or to the shorter period of follow up. An alter-
native explanation is that the aggressive treatment of CFRD
may have masked its effect on lung function. This hypoth-
esis is consistent with the results of Lanng and
coworkers36,37 showing that patients with CF had decline in
pulmonary function for as long as 6 years before the diag-
nosis of CFRD and that pulmonary function improved once
therapy with insulin was instituted.
There are some limitations to the current study which
should be mentioned. First, our study is a retrospective
study, and this could entail a possible loss of information on
exacerbations. However, in our Center, CF patients are very
tightly followed up, and patients are instructed to attend
outpatient clinic in the event of respiratory symptom
worsening, or appearance of other signs and symptoms of
exacerbations, thus we are quite confident that all exac-
erbations have been included in our analysis; nevertheless,
the possibility that some very mild exacerbations were not
detected and, therefore, were not recorded cannot be
discarded entirely. We do not believe that the final
conclusions would be altered in this case, however. Second,
the patients studied were recruited from a single Centerand their number is limited; however, with a mean of 5
observations for each subject, our analysis is based on
a total of 256 observations in a repeated measure design (a
very powerful design in measuring the within subjects
effects and enough powerful in measuring the between
subjects effect). Third, the patients studied are all adult
patients, and in a significant number of them CF was
diagnosed after the age of 18; these patients had clinical
characteristics of mild disease, which may be a limitation
for generalizing the study results in particular in a younger
patient population. Finally, some of relevant variables such
as extent and severity of bronchiectasis, dose and duration
of antibiotic treatment were not included in our analysis.
Therefore, we believe that larger, multicentric studies
including more patients and additional variables are
needed in order to further define the factors responsible for
lung function decline in CF patients.
In conclusion, the results of our study support the
concept that beside CFTR defect, environmental factors,
including treatment strategies, are important determi-
nants of lung function impairment. Whereas a further
identification of the factors responsible for lung function
decline is a major goal of CF research, overall ours and
previous studies suggest that the aggressive and intensive
treatment of disease exacerbations is crucial not only for
decreasing mortality in CF, but also for delaying lung
function decline.Conflict of interest statement
Dr. De Rose has been reimbursed by pharmaceutical
companies (Boehringer Ingelheim, Dompe´, Glaxo-SmithK-
line) for attending some conference; VDR’s institution has
received an unrestricted educational grant from Glaxo-
SmithKline. Dr. Amadori has no conflicts of interest to
disclose.
Dr. Antonelli has no conflicts of interest to disclose. Dr.
Balteri has no conflicts of interest to disclose. Dr. Schreiber
has no conflicts of interest to disclose. Dr. Bugiani has no
conflicts of interest to disclose.
References
1. Davis PB, Drumm K, Konstan MW. Cystic fibrosis: state of the
art. Am J Respir Crit Care Med 1996;154:1229e56.
2. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681e9.
3. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic
variations. Annu Rev Genet 1995;29:777e807.
4. Kerem E, Kerem B. Genotypeephenotype correlation in cystic
fibrosis. Pediatr Pulmonol 1996;22:387e95.
5. Corey M, Edwards L, Levison H, Knowles M. Longitudinal anal-
ysis of pulmonary function decline in patients with cystic
fibrosis. J Pediatr 1997;131:809e14.
6. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the
relationship between survival and pulmonary function in cystic
fibrosis patients. Stat Med 2002;21:1271e87.
7. Nelson LA, Callerame ML, Schwartz RH. Aspergillosis and atopy
in cystic fibrosis. Am Rev Respir Dis 1979;120:863e73.
8. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmo-
nary aspergillosis in cystic fibrosis e state of the art: Cystic
Fibrosis Foundation Consensus Conference. Clin Infect Dis
2003;37(Suppl. 3):S225e64.
FEV1 decline in cystic fibrosis 4139. Beharry S, Ellis L, Corey M, Marcon M, Durie P. How useful is
fecal pancreatic elastase 1 as a marker of exocrine pancreatic
disease? J Pediatr 2002;141:84e90.
10. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and
management of cystic fibrosis related diabetes mellitus:
a consensus conference report. Diabetes Res Clin Pract 1999;
54:61e73.
11. Doring G, Conway SP, Heijerman, et al. Consensus statement:
antibiotic therapy against Pseudomonas aeruginosa in cystic
fibrosis: a European consensus. Eur Respir J 2000;16:749e67.
12. De Rose V, Oliva A, Messore B, Grosso B, Mollar C, Pozzi E.
Circulating adhesion molecules in cystic fibrosis. Am J Respir
Crit Care Med 1998;157:1234e9.
13. Cystic Fibrosis Foundation. Clinical practice guidelines for
cystic fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
14. American Thoracic Society. Standardization of spirometry,
1994 update. Am J Respir Crit Care Med 1995;152:1107e36.
15. De Rose V, Arduino C, Cappello N, et al. Fcgamma receptor IIA
genotype and susceptibility to P. aeruginosa infection in
patients with cystic fibrosis. Eur J Hum Genet 2004;13:96e101.
16. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal
modeling using Stata-Cho 3e3 linear random-coefficient and
growth-curve models. College Station, Texas, USA: Stata
Press; 2005.
17. Twisk JWR. Applied longitudinal data analysis for epidemi-
ology. Cambridge, UK: Cambridge University Press; 2003.
18. Demko CA, Byard PJ, Davis PB. Gender difference in cystic
fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol
1995;48:712e8.
19. Davis PB, Byard PJ, Konstan MW. Identifying treatments that
halt progression of pulmonary disease in cystic fibrosis. Pediatr
Res 1997;41:161e5.
20. Zemel BS, Jaward AF, FitzSimmons S, Stallings VA. Longitudinal
relationship among growth, nutritional status, and pulmonary
function in children with cystic fibrosis: analysis of the Cystic
Fibrosis Foundation National CF Patients Registry. J Pediatr
2000;137:374e80.
21. Steinkamp G, Wiedemann B. Relationship between nutritional
status and lung function in cystic fibrosis: cross sectional and
longitudinal analyses from the German CF quality assurance
(CFQA) project. Thorax 2002;57:596e601.
22. Schaedel C, de Monestrol I, Hjelte L, et al. Predictor of dete-
rioration of lung function in cystic fibrosis. Pediatr Pulmonol
2002;33:483e91.
23. Lewin LO, Byard PJ, Davis PB. Effects of Pseudomonas cepacia
colonization on survival and pulmonary function of cystic
fibrosis patients. J Clin Epidemiol 1990;43:125e31.
24. Kerem E, Corey M, Gold M, Levison H. Pulmonary function and
clinical course in patients with cystic fibrosis after pulmonarycolonization with Pseudomonas aeruginosa. J Pediatr 1990;
116:1653e8.
25. Downey DG, Martin SL, Dempster M, et al. The relationship of
clinical and inflammatory markers to outcome in stable patients
with cystic fibrosis. Pediatr Pulmonol 2007;42:216e20.
26. Konstan MJ, Morgan WJ, Butler SM, et al. Risk factors for rate
of decline in forced expiratory volume in one second in chil-
dren and adolescents with cystic fibrosis. J Pediatr 2007;151:
134e9.
27. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M,
Roman-Sanchez P, Soriano J. Factors associated with lung
function decline in adult patients with stable non-cystic
fibrosis bronchiectasis. Chest 2007;132:1565e72.
28. Ellaffi M, Vinsonneau C, Coste J, et al. One-year outcome after
severe pulmonary exacerbation in adults with cystic fibrosis.
Am J Respir Crit Care Med 2005;171:158e64.
29. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary
exacerbations. J Pediatr 2006;148:259e64.
30. De Rose V. Mechanisms and markers of airways inflammation in
cystic fibrosis. Eur Respir J 2002;19:333e40.
31. Downey DG, Brockbank S, Martin L, Ennis M, Elborn JS. The
effect of treatment of cystic fibrosis pulmonary exacerbations
on airways and systemic inflammation. Pediatr Pulmonol 2007;
42:729e35.
32. Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in
bronchiectasis: correlation between computed tomography
features and pulmonary function tests. Thorax 2000;55:
198e204.
33. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on
high resolution computed tomography despite stable lung
function in cystic fibrosis. Eur Respir J 2004;23:93e7.
34. Martinez-Garcia MA, Perpina-Tordera M, Soler-Cataluna JJ,
Roman-Sanchez P, Lloris-Bayo A, Gonzales-Molina A. Dissocia-
tion of lung function, dyspnea ratings and pulmonary extension
in bronchiectasis. Respir Med 2007;101:2248e53.
35. Navarro J, Rainisio M, Harms HK, et al. Factors associated with
poor pulmonary function: cross-sectional analysis of data from
the ERCF. Eur Respir J 2001;18:298e305.
36. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in
cystic fibrosis: effects of insulin therapy on lung function and
infections. Acta Pediatr 1994;83:849e53.
37. Lanng S, Thorsteinson B, Nerup J, Koch C. Influence of the
development of diabetes mellitus on clinical status in patients
with cystic fibrosis. Eur J Pediatr 1992;151:684e7.
38. Koch C, Rainisio M, Madessani U, et al. Presence of cystic
fibrosis-related diabetes mellitus is tightly linked to poor lung
function in patients with cystic fibrosis: data from the Euro-
pean Epidemiologic Registry of cystic fibrosis. Pediatr Pulmo-
nol 2001;32:343e50.
